• MULN shares traded higher after Benzinga stated that the emerging EV manufacturer had reported higher-than-expected battery test results
• Data shows the company’s proprietary solid-state polymer batteries can deliver more than 600 miles of range on a full charge
• The company plans to include the new batteries in its second-generation Mullen FIVE EV Crossover

Mullen Automotive (NASDAQ: MULN) was featured in a recent Benzinga Brief. The short summary noted that the company, an emerging electric-vehicle manufacturer, had reported results of its solid-state polymer battery testing, which exceeded expectations (https://ibn.fm/XI6Fa). Noting that shares were trading higher after the news, Benzinga quoted David Michery, Mullen CEO and chair, as saying, “The battery has performed exceptionally well, and I’m pleased with the results from BIC [Battery Innovation Center] in Indiana.” “Testing results from BIC show the solid-state polymer cell, rated at 300 Ah and 3.7 volts, tested at 343.28 Ah at 4.2 volts, exceeding expectation, and is in line with test tolerance from previous EV Grid test results,” the brief continues. “The data supports solid-state polymer battery cell technology [that], when scaled to the vehicle pack level and at a 150-kilowatt hour equivalent, can deliver over 600 miles of range on a full charge for the Mullen FIVE EV Crossover.” While the company plans to continue to test additional parameters to characterize overall capabilities and performance, these positive results bode well for the Southern California–based company, which owns and partners with synergistic businesses that share the same goal: to create clean, scalable electric vehicles and energy solutions (https://ibn.fm/D8vYz). The company announced plans to include the new solid-state polymer batteries in its second-generation Mullen FIVE EV Crossover (https://ibn.fm/Br0nl). In addition to offering more than 600 miles of range, the batteries can deliver 300 miles of range after an 18-minute DC fast charge. “We’ve conducted successful testing and will begin pack-level development next,” said Michery, who called the future bright for the nascent EV company. Key to the company’s success are several partnerships the company has built recently, including with hofer powertrain, Comau, ARRK, Dürr and DSA Systems. These partners will help Mullen produce improved EV powertrain, engineering, manufacturing, vehicle production systems, and over-the-air (“OTA”) and vehicle system diagnostics. “[Mullen] expects these strategic developments to play a crucial role in bringing the FIVE to market with the latest technology and in the shortest amount of time,” the company stated. The Mullen FIVE RS is a high-performance EV featuring close to 1,100 horsepower, 0 to 60 mph in only 1.95 seconds, and a top speed of almost 200 miles per hour (https://ibn.fm/KaCIj). The vehicle was awarded Top Zero Emission SUV as part of the ZEVA Awards at the Los Angeles International Auto Show in November 2021, where it debuted. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• Fossil fuels still account for about 80% of primary energy worldwide. They are responsible, on a per capita basis, for 63,130kWh of energy in the United States, with renewables onlyaccounting for 8,266 kWh
• The United States, prior to the recent ban, had 8% of its total petroleum imports (including crude oil) coming from Russia, a reliance that has now resulted in significant increases in gasoline and diesel prices
• Correlate, through its distributed clean energy solutions, is addressing these issues, helping to bring society closer to significantly less dependence on the national grid and more on green energy sources
• The company is capitalizing on the momentum of growing wind, solar, and even geothermal power production, to grow its market share, strengthen its brand equity, and diversify its product offering
• By providing energy programs for commercial property portfolios that require no upfront capital on the part of the customer, Correlate continues to build its appeal to potential clients, laying down a template that can be easily replicated and implemented in various sectors

Energy security and affordability have become increasingly critical factors for nations around the world. The Russia-Ukraine issue has pointed out how overreliance on specific energy supplies can be detrimental to national economies, and how bad the situation could get if geopolitical and other problems were to accelerate. Fossil fuels still account for about 80% of primary energy worldwide. The main source is oil, followed by coal, and it is further projected that this will continue to be the case for a long time. The United States, for instance, uses 63,130kWh of energy, per capita, from fossil fuels, with renewables only accounting for 8,266 kWh. Similar disparities are found in other countries, including, but not limited to, Canada, China, Japan, Australia, and the UK (https://ibn.fm/XxMAZ). This overreliance on fossil fuels presents international supply chain risks and challenges, affected by unexpected changes in linkages between energy markets. The U.S., prior to the recently imposed ban, had 8% of its total petroleum imports (including crude oil) coming from Russia. With the ongoing issue in Ukraine, this reliance and associated ban has caused issues with supply, ultimately resulting in a significant jump in gasoline and diesel prices (https://ibn.fm/cjiVv). Many other countries, of course, face the challenge of considerably more dependence. Correlate Infrastructure Partners (OTCQB: CIPI), a company offering a complete suite of proprietary clean energy assessment solutions for the commercial real estate industry, is committed to bringing society closer to less dependence on the national grid and, by extension, fossil fuels, to focus demand more on green energy sources. With its distributed clean energy solutions, the company believes that it can help mitigate the effects of climate change while at the same time ensuring that businesses, both big and small, have access to clean and reliable energy. A report published by Frontier Group and Environment America Research and Policy Center, noted that between 2011 and 2020, the proportion of electricity generated from wind and solar in the U.S. increased by about four times. More specifically, the study noted that wind, solar, and geothermal power production grew yearly by 15%, which by 2035 could meet the country’s electricity demand (https://ibn.fm/JgD9Y). Correlate looks to make the most out of growing consumer realization of the overreliance on fossil fuels, to build its customer numbers given its unique product offering, and to thus grow its market share, strengthen its brand equity, diversify its product offerings, and create value for its shareholders. So far, Correlate and its subsidiary, Solar Site Design, have an opportunity pipeline of over $100 million in commercial products, with over $20 million in awarded backlog. With more corporations realizing the benefits associated with alternative energy sources, specifically solar power, Correlate is confident that its opportunity pipeline will continue to grow, as will its customer base. By providing energy programs for commercial property portfolios requiring no upfront capital, Correlate is appealing to more potential clients while continually reducing the barrier of entry, encouraging a much-needed energy transition. The company understands its clients’ hurdles and seeks to address them to reduce demand dependence on fossil fuels and to increase the uptake of greener, more sustainable energy alternatives. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The rice production industry is under an imminent threat due to increased demand and reduced crop yields
• With Thailand, the Philippines, and China all facing problems in rice production, a lot rides on the success of India’s rice crops, despite the uncertainty of monsoon and harvest season
• FuelPositive Corp. is currently developing proprietary green ammonia technology driving for on-site fertilizer production and zero carbon emissions

The rice production industry faces multiple imminent threats worldwide, including rising fertilizer costs, climate change, and increased demand when crop yields seem to be declining. These threats pose a potential risk to food security and the efforts being made to contain inflation. Countries such as Thailand, China, India, and the Philippines, are already dealing with mounting concerns, due to the lower crop yields, climate change, invasion of pests, and the rising cost of crop nutrients. Most of the world’s rice is grown, eaten, and exported from Asia, making political stability in the region crucial to production efforts (https://ibn.fm/vQaoa). With the current status of the contributing countries, much is riding on India’s rice crop, which ships approximately 40% of the world’s exports in rice. Although India has limited wheat crops, the rice exports are helping ease the reduction in supply within the region. Should the wheat harvest be limited more due to the monsoon rains necessary for harvest season, it is possible that rice will be needed to supplement for food and livestock feed. According to Vice President and researcher V. Subramanian of The Rice Trader, “Global supply is at risk, but for now, we still have massive Indian availability that is reining in prices. Looking at the current situation, India is acting as an anchor for prices with its large exports.” The high prices for fertilizer and the inherent presence of climate change are driving factors for FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) message that fossil fuels don’t only damage the climate, but make the world economically vulnerable. FuelPositive is a growth-stage company focused on partnership and acquisition opportunities for energy efficiency and sustainability technologies. The company’s emphasis on economic vulnerability and climate change can be supported through the AR6 Synthesis Report (https://ibn.fm/tSc8e). Carbon emissions are the leading cause of climate change and global warming issues worldwide. The company’s Hydrogen-Ammonia Synthesizer technology provides the means necessary to store green hydrogen as green ammonia that is completely carbon-free. The hydrogen can be removed when needed for use in fuel cells and other applications based on pure hydrogen technologies. In the same way that ammonia is the perfect carrier for hydrogen, it is also the perfect carrier for nitrogen – the key component in fertilizers. FuelPositive has developed a containerized green ammonia production system relying on renewable electricity to synthesize hydrogen from water and nitrogen from the air before combining the two elements in a proprietary converter to form ammonia. The technology will allow farmers to economically produce the amount of ammonia needed to fertilize their crops on-site. In doing so it eliminates supply chain dependence, and stabilizes price while eliminating carbon emissions. The system can be scaled up or down, so farmers can produce the amount of fertilizer they need right on their farms and apply it when the timing is best. The first demonstration systems are being built to produce up to 300 kg/day, which amounts to 100 metric tonnes per year. FuelPositive expects to begin on-farm demonstration of its proprietary green ammonia production systems in fall 2022. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Lexaria Bioscience Corp. expects the upcoming human nicotine study to produce evidence that its patented DehydraTECH(TM) technology can enhance oral-tissue absorption with reduced negative experiences
• Data collected from animal study NIC-A21-1 showed that DehydraTECH enhanced oral nicotine pouches delivered peak nicotine levels in the bloodstream of animals 10x to 20x faster than the control
• The global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, being one of the fastest growing segments in the nicotine industry
• Lexaria’s pipeline addresses serious unmet patient or consumer needs with greater market potential, addressing multiple mainstream applications in cannabinoids, oral nicotine, antiviral therapies, phosphodiesterase inhibitors, and other APIs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the pending start of an upcoming human nicotine study, NIC-H22-1. The company expects to evidence that processing purified nicotine with its patented DehydraTECH(TM) technology leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1 is a minimum 36-person human pharmacokinetic randomized, double-blind, cross-over study comparing DehydraTECH-nicotine pouch performance to existing brands currently on the market, including ON! and Zyn (https://ibn.fm/aFVPk). The study’s primary objective is the objective data collection from blood samples that will evidence Tmax, Cmax, and AUC. Other study objectives include extensive subjective evaluations related to complaints of throat burn, user experience, and more. The nicotine test article ingredient manufacturing and DehydraTECH processing have been completed, and the materials have been received by the third-party pouch manufacturing company for filling and packaging. This study’s next two major steps will be Independent Review Board approval and subsequent human dosing. Through a previous animal study NIC-A21-1, the company has already demonstrated that oral nicotine pouches using DehydraTECH technology were 10x to 20x faster at reaching peak delivery of nicotine to the bloodstream than the control. Lexaria is leveraging the oral nicotine pouch market, which is one of the fastest growing segments in the nicotine industry due in part to the US Food and Drug Administration’s note of “reduced risk health outcomes” (https://ibn.fm/SmOJi). The delivery method, specifically the white pouch format, avoids harmful lung outcomes experienced by smokers and vapers, only involving absorption primarily through the mouth’s buccal tissues through purified nicotine. In 2020, the global nicotine pouches market was valued at $2.33 billion and is expected to reach $21.84 billion by the end of 2027, growing at a CAGR of 30.7% during the forecast period. (https://ibn.fm/a8Wc0). On March 8, 2022, Lexaria announced that it had been granted a new patent, “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” The Australian patent expands Lexaria’s international intellectual property rights to apply DehydraTECH enhancement technology to most oral forms of nicotine, including pills, lozenges, capsules, pouches, gums, and sprays. Lexaria currently has 25 patents granted worldwide plus a 26th patent allowed in Japan. As detailed in Lexaria’s July 2022 Corporate Presentation, DehydraTECH is faster and more effective at delivering drugs into the bloodstream and brain tissues by increasing bioavailability, improving the speed of onset, reducing drug administrative costs, and masking the unwanted taste (https://ibn.fm/QptMW). The technology’s pipeline addresses serious unmet patient needs with greater market potential, addressing multiple mainstream applications in cannabinoids, oral nicotine, antiviral therapies, phosphodiesterase inhibitors, and other APIs. The current pipeline includes five studies currently in various stages, including animal PK/PD proof of concept for CBD for epilepsy and PDE5 inhibitors, human PK/PD proof of concept for oral nicotine (NIC-H22-1), and one study currently in the Investigational New Drug (“IND”) enabling study status, DehydraTECH-CBD for hypertension. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• NOWG signs MOU creating a strategic business partnership that will deliver value in India’s growing CSR market
• India has made CSR obligatory, requiring top companies that meet specific requirements to spend 2% of their normal net benefits on CSR initiatives annually
• The company announces the creation of the Nowigence Independent Growth Council

As evidence of its continued commitment to and progress toward becoming a gamechanger in the global data gathering and analysis space, Nowigence (OTCQB: NOWG) has made two key announcements. First, Nowigence signed a memorandum of understanding (“MOU”) with India-based EquiPPP Social Impact Technologies Ltd. (https://ibn.fm/NiyLD). Second, Nowigence has formed an independent growth council to advise, strategize and assist with delivery of its growth plan (https://ibn.fm/K4x3L). The MOU is designed to create a strategic business partnership in which EquiPPP will “act as a business development partner promoting Nowigence products in India and tailoring its core machine learning and natural language processing engine to develop information technology (‘IT’) and ITeSaaS (information technology enabled software as a service) products for corporate social responsibility (‘CSR’) activities, granting EquiPPP exclusive marketing rights for those CSR products in India,” Nowigence explained. EquiPPP is a publicly listed company that provides software services, is engaged in IT and ITeSaas, and offers a digital platform enabling various stakeholders to collaborate in implementing CSR projects. “We are happy to partner with EquiPPP to deliver value in the growing CSR market while benefiting society at large,” said Nowigence CEO Anoop Bhatia. “We are excited to jointly bring technology into the social programs space. Together, we hope to make a significant difference in our collective social responsibility, connecting donors and service organizations to improve the lives of the underprivileged.” India has made CSR obligatory, requiring top companies that meet specific requirements —annual revenues of more than $140 million, assets of more than $70 million or net benefits exceeding $700,000 — to spend 2% of their normal net benefits on CSR initiatives annually. This creates an ideal entry point for Nowigence, which has demonstrated expertise in artificial intelligence (“AI”), machine learning (“ML”) and natural language processing (“NLP”). As evidence of this expertise, NOWG has created Pluaris, a cutting-edge intelligent reader that mimics in real time the human process for knowledge assimilation while conducting a smart search. In addition, Nowigence announced the creation of the Nowigence Independent Growth Council, a group of industry experts with impressive experience in building successful tech companies. Members of the new council include Michael Connolly, Rohit Kumar, Tinsley Galyean, Girdhar Gopal Das, Gordon (Gordy) Haupt, Uday Bawa, David L. Evans, Tracy Metzger, Ian Moore and Anoop Bhatia. “We are shifting gears in our growth journey,” said Bhatia. “The announcement of the growth council aims to provide co-benefits to our customers with value-driven innovation in the fields of machine learning and natural language processing.” Nowigence is an innovative software as a service (“SaaS”) company, focused on developing and bringing to market Pluaris, its comprehensive, ready-to-use artificial intelligence platform. By integrating state-of-the-art data-processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to NOWG are available in the company’s newsroom at https://ibn.fm/NOWG

• As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ condition
• While efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injury
• Odyssey is enrolling patients in a Phase 1 human clinical trial after completing pre-clinical studies in laboratory animals
• The medical research company’s assets include treatments for patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats and patients dealing with a rare neurodegenerative disorder

Sports-related concussions have gained a growing degree of attention during the past decade, thanks largely to the activism of a junior high school football player severely injured during a game who continued to play despite a hard impact to the head he had experienced (https://ibn.fm/bb79K). His story led to what has become known as the Lystedt Law, a series of head safety standards for youth athletes pioneered in Washington state and eventually adopted by all 50 states. Among professional athletes, concerns have been raised by players such as former Team U.S.A. soccer forward Bruce Murray’s, whose efforts to raise concussion awareness stem from head injuries he believes have left him with chronic traumatic encephalopathy (“CTE”), an incurable condition characterized by trouble with memory, problems organizing and planning simple activities, and changes in behavior, such as lack of motivation or having a short temper, but only truly diagnosable in deceased patients (https://ibn.fm/aAPGU). Former Denver Broncos football player Demaryius Thomas was one such athlete diagnosed with CTE after his death (https://ibn.fm/P9ziU). Head impact injuries can affect athletes in a wide variety of sports, and numerous enterprises have manufactured devices designed to help measure injury among them. Head Impact Trauma Ltd. founder Euan Bowen, for example, was inspired by his rugby experience to create a headband and sensor system that measures cranial G-force but his product has been adopted by downhill mountain bike racers as well (https://ibn.fm/M9X6t). And a group of engineering students at Old Dominion University created an award-winning accelerometer designed to be affordable even for small schools interested in assessing head impacts in young players (https://ibn.fm/LHuAz). Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) is focusing on the concussion injury issue from the vantage point of treating individuals after they’ve been hurt. There is no medication approved by the U.S. Food and Drug Administration (“FDA”) at this point for treating specific concussion injuries, but Odyssey is preparing for human trials of a product it believes may fill that gap. “We provide a clinical advantage in the marketplace,” CEO Michael Redmond told The RedChip Money Report(R) on Bloomberg TV last month. “We have a very unique new chemical entity intended to treat mild traumatic brain injury — the acute phase of a concussion. It’s a small device. It essentially goes and delivers a powderized drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within five minutes. It spreads out throughout the brain within 30 minutes and reverses the effects of a concussion” (https://ibn.fm/sZXWV). The Phase 1 clinical trial is enrolling 48 patients and will follow completed preclinical lab animal testing. Odyssey also is developing a prototype device for diagnosing heart disease and another for saving people choking on an obstruction that it hopes to have before the FDA for approval by year’s end. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

Canada Crypto Week is taking place August 8-14, 2022, showing the crypto world that Canada is back in action with some of the brightest minds in the industry. Coordinated by Untraceable Events,  it is a week to encourage event organizers to host crypto and blockchain related events, and to encourage crypto enthusiasts to attend a variety of shows so they can network and grow the ecosystem. With Blockchain Futurist Conference and ETHToronto being the anchor events of the week, already bringing in thousands of tech enthusiasts from around the globe, it is an ideal time to host Canada Crypto Week. August is an especially great month for Canada, with mild temperatures and less interference with events in other countries. Together, these events represent great networking and business opportunities, hosted by Untraceable Events, a global company organizing blockchain and cryptocurrency events in Canada since 2013. Such networking symposiums are hugely important, and need to be encouraged and supported throughout Canada, with more dates and topics being the best way to expand the ecosystem. In the case of crypto, it’s the best way to get to know the space and learn about projects, with smaller events often able to narrow in on more specific topics of interest, such as deFi, the Metaverse or NFTs. Canada Crypto Week is a phenomenal platform to encourage and inspire the cryptocurrency trade and vendors in Canada, showcasing the growing cryptocurrency community on a global forum. Canada Crypto Week invites vendors, businesses, and enthusiasts of the cryptocurrency arena to participate in and boost crypto trade. Events currently registered for Canada Crypto Week include:

• Official Opening Crypto Ecosystem Night Back To The Futurist by Virgo, Toronto, August 8
• ETHToronto, Toronto, August 8-10
• Blockchain Futurist Conference, Toronto, August 9-10
• ST4M1NA & MADISON: The Future of Real Estate, Arts, and NFTs, August 8-14
• BitBoy Meetup at Futurist, Toronto, August 9
• Blockchain Bootcamp, Toronto, August 9
• Web3 TO Networking, Toronto, August 9
• Telos Meetup at Futurist, Toronto, August 10
• Cabana Closing Party, Toronto, August 10
• Bitcoin for Beginners, Calgary, August 11
• Crypto Babes, Toronto, August 11

Check out the official website www.canadacryptoweek.com to view all the events of the week or to submit an event of your own! We look forward to seeing the crypto world come back to life in Canada back to life and become a global leader in the industry as we have in the past. Those looking to host a related event in Canada from August 8-14 can reach out to https://forms.gle/k8h3kESKqQY3bZdQ9. Those looking to sponsor an event for the Blockchain Futurist Conference can reach out to events@untraceableinc.com. To learn more about the Futurist Conference, please visit https://www.futuristconference.com/.

• D-Wave Systems Inc. is the world’s first commercial supplier of quantum computers
• The company’s customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin
• The Advantage(TM) Quantum Computer is currently on its 5th generation, featuring 2.5x more connections and more than double the number of qubits of its predecessor
• Leap(TM) delivers immediate, real-time enterprise access to the company’s Advantage quantum computer through the cloud
• D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corp., Aegis Group Partners and In-Q-Tel
• The global quantum computing market is forecast to reach $3.2 billion by 2028, expanding at a CAGR of 30.8% from 2021

DPCM Capital (NYSE: XPOA), a special purpose acquisition company, on February 9, 2022, announced its entry into a definitive transaction agreement with D-Wave Systems Inc., a company with approximately 20 years of experience in pioneering superconducting annealing quantum computers. Upon closing of the transaction, shares of D-Wave Quantum Inc. – a newly formed company that will be the parent company of D-Wave Systems and DPCM Capital – are expected to trade on the NYSE under ticker symbol ‘QBTS’. The transaction, which is subject to the satisfaction of customary closing conditions, is expected to enhance D-Wave’s leadership in commercial quantum computing and accelerate quantum use cases into significant customer segments. D-Wave is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow. D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage(TM) (fifth generation quantum computer), Leap(TM) (quantum cloud service), Launch(TM) (quantum computing onboarding service) and Ocean(TM) (full suite of open-source programming tools). D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave. D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals. Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California. Advantage(TM) Quantum Computer With the Advantage(TM) Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer. D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap(TM) quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States. That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (“QCC”) hosted at USC’s Information Sciences Institute (“ISI”), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (“AWS”) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users. Leap Quantum Cloud Service D-Wave’s customers interface with its systems through the Leap(TM) quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability. Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints. Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward. D-Wave Launch D-Wave Launch(TM) is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot. From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value. Target Verticals While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases. Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing. D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors. D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel. Leadership Team Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology. John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business. For more information, visit the D-Wave Systems website at www.DWaveSys.com. NOTE TO INVESTORS: The latest news and updates relating to XPOA are available in the company’s newsroom at https://ibn.fm/XPOA

Witness the magical out-of-the-world experience of outer space at the NFT Expoverse, being held at the Los Angeles Convention Center from July 29-31, 2022. Industry leaders, entrepreneurs, techies, visionaries and professionals from the fields of Web 3.0, blockchain, and NFT technologies, are all invited to attend this Expoverse. The Space Giveaway Event Horizon, part of the NFT Expoverse, is a wonderful opportunity for those who have always dreamt of a chance to win a free trip into outer space. The 1st prize of the Space Giveaway (diamond NFT) is an amazing 12-hour space journey, wrapped in a 5-day experience, where the winner will travel in a zero-pressure stratospheric balloon. Spaceflights take off before dawn from World View Spaceports and travel to 100,000 feet above Earth. You can enjoy the edges of outer space for hours as you take in the blackness of space and witness the vast curved expanse of the Earth. It will indeed be the experience of a lifetime, and includes Astronaut Training & Galactic Visionaries Charter Membership. The 2nd place (Platinum NFT) winner will be science popularist Bill Nye’s guest for a special tour of The Planetary Society’s HQ located in the “city of astronomy,” Pasadena, California (flight and hotel stay included). You’ll sip his favorite coffee with Bill, discuss the cosmos and the great questions like “where did we come from?” and “are we alone in the universe?” You’ll leave with a selfie with Bill, cool space swag, and a one-year, mind-expanding Planetary Society membership. The 3rd place winner (Gold NFT) will receive a flying lesson where they will learn to fly and float from an FAA-certified flight instructor. This zero-gravity experience is like no other. Get trained by experts in simulated “zero-g” by flying a series of parabolic flight maneuvers in the Rockwell Commander 700 that counter the forces of gravity. The winner gets to decide the launch date. Experience the weightlessness of space (subject to weather permitting and the availability of the pilot). The event is organized by ZJ Events, a pioneer in hosting conferences and seminars that foster B2B and B2C networking across verticals of the event’s target industry. The event partners are The Planetary Society, Astronaut, Lunar, and World View. The winner must be physically present at NFT Expoverse to accept the Diamond Prize. Winners of the Platinum and Gold prizes can accept their winnings via video call. Winners will be announced live at the event on July 30th, 2022. To participate in the event, purchase your NFT Expoverse tickets and to learn more about the event, please visit https://ibn.fm/SE3Sk.

• Treating patients with primary or secondary bone cancer remains goal, says company CEO
• Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cells
• QSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients

QSAM Biosciences (OTCQB: QSAM), a company developing a new class of drugs called radiopharmaceuticals, is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its proprietary radiopharmaceutical technology: CycloSam(R). “This is an important milestone for QSAM,” said QSAM cofounder and CEO Douglas R. Baum (https://ibn.fm/GcD0R). “Successfully treating patients with primary or secondary bone cancer remains an area of significant unmet medical need and a goal for CycloSam(R).” QSAM received Investigational New Drug Application (“IND”) approval from the U.S. Food and Drug Administration (“FDA”) and shortly thereafter activated its planned phase 1, open-label, dose-escalation, multicenter clinical trial. The trial will study patients who have been diagnosed with bone cancer, including cancer that has metastasized from the lung, breast or prostate, and will evaluate the safety, tolerability, dosimetry and preliminary efficacy of CycloSam. Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly and specifically to cancer cells. “The last several years have seen an explosion of research and clinical trials testing new radiopharmaceuticals,” reports a recent National Cancer Institute (“NIH”) article (https://ibn.fm/nJsjs). The article noted that radiation therapy was first used to treat cancer more than a century ago, with approximately one-half of all cancer patients still receiving it at some point during their treatment. “Until recently, most radiation therapy was given much as it was 100 years ago, by delivering beams of radiation from outside the body to kill tumors inside the body,” noted the NIH article, which observed that external radiation can cause collateral damage because normal tissue is radiated along with the cancerous tissue. “The resulting side effects of radiation therapy depend on the area of the body treated but can include loss of taste, skin changes, hair loss, diarrhea and sexual problems,” the article continued. New research and studies indicate that “targeting radiation therapy at the cellular level has the potential to reduce the risk of both short- and long-term side effects of treatment while at the same time enabling even tiny deposits of cancer cells to be killed throughout the body.” It is this approach that QSAM focuses on with its lead drug candidate, CycloSam, which is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone (https://ibn.fm/ZRteN). According to the company, CycloSam delivers Samarium-153, a beta-emitting radioisotope, to areas of rapid bone formation through a superior chelant, DOTMP. The treatment is believed to provide a controlled dose of radiation directly to the tumor environment while minimizing radiation exposure to healthy tissue. The desired goal is tumor regression and increased survival of the patient, results that will be evaluated in the clinical trial process. “Every day our teams are working toward developing CycloSam as a breakthrough therapeutic for cancer patients, both children and adults, male and female, who unfortunately still have poor options and limited long-term survival prognosis,” said Baum. “We look forward to sharing the results of this study with our shareholders and the medical community.” For more information, visit the company’s website at www.QSAMbio.com. NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM